[PPT] - Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc A PowerPoint Presentation

SLIDE 1

1

A

Shire Pharmaceuticals Group plc Shire Pharmaceuticals Group plc

First quarter results ended 31 March 2001 First quarter results ended 31 March 2001

SLIDE 2

2

A

Rolf Stahel Rolf Stahel Chief Executive Shire Pharmaceuticals Group plc Chief Executive Shire Pharmaceuticals Group plc

SLIDE 3

3

A Comment on the “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995 Comment on the “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

The statements made during today’s presentation, or in response The statements made during today’s presentation, or in response to to questions during the Question & Answer period, that are not questions during the Question & Answer period, that are not historical facts, are forward historical facts, are forward-

looking statements that involve risks and

looking statements that involve risks and uncertainties, including but not limited to, risks associated wi uncertainties, including but not limited to, risks associated with the th the inherent uncertainty

f

pharmaceutical research, product inherent uncertainty

f

pharmaceutical research, product development and commercialisation, the impact of competitive development and commercialisation, the impact of competitive products, patents, and other risks and uncertainties, including products, patents, and other risks and uncertainties, including those those detailed from time to time in periodic reports, including the An detailed from time to time in periodic reports, including the Annual nual Report filed on Form 10K by Shire with the Securities and Exchan Report filed on Form 10K by Shire with the Securities and Exchange ge Commission. Commission.

SLIDE 4

4

A

This presentation does not constitute an offer to sell or issue, or a solicitation of any offer to purchase or subscribe for, any ordinary shares in the Company, nor shall it form the basis of, or be relied upon in connection with, any contract for such purchase or subscription. No representation or warranty, express or implied, is made or given by the Company as to the accuracy or completeness of the information or the opinions contained in this presentation and no liability is accepted for any such information or opinions. This document has been issued by, and is the sole responsibility of, Shire Pharmaceuticals Group plc. This document has been approved by Deutsche Bank AG London (“Deutsche Bank”) solely for the purposes of section 57 of the UK Financial Services Act 1986. Deutsche Bank, which is regulated in the United Kingdom by the Securities and Futures Authority Limited, is acting for Shire and no one else in connection with the Merger and will not be responsible to anyone other than Shire for providing the protections afforded to customers of Deutsche Bank nor for providing advice in relation to the Merger. Persons viewing this document are directed to the Shire press announcement dated 11 December 2000, which contains additional details and information relating to the Merger.

Section 57 Financial Services Act Section 57 Financial Services Act

SLIDE 5

5

A Q1 Financial Highlights (before APB 25 charge) Q1 Financial Highlights (before APB 25 charge)

Revenues

$155.6m +31%

Operating income

$ 42.0m +44%

Income before tax

$ 40.1m +50%

EPS (diluted)

Ordinary shares

10.7 cents +46%

ADS

32.1 cents

Revenues

$155.6m +31%

Operating income

$ 42.0m +44%

Income before tax

$ 40.1m +50%

EPS (diluted)

Ordinary shares

10.7 cents +46%

ADS

32.1 cents

SLIDE 6

6

A Key Product RX Market Share Key Product RX Market Share

+43 26.0 32.5

Carbatrol

+31 19.5 22.1

ProAmatine

+10 18.0 17.8

Pentasa

+42 14.3 20.4

Agrylin

+20 29.7 33.3

Adderall

RX growth Q1 01 versus Q1 00* % March 00 % March 01 %

IMS data

SLIDE 7

7

A

Central Nervous System

ReminylTM (galantamine) Alzheimer’s disease DirameTM Analgesia Adderall LA (SLI 381) ADHD SPD 503 ADHD SPD 420 ADHD SPD 417 Bipolar disorder SPD 418 Epilepsy SPD 421 Epilepsy SPD 451 Parkinson’s Disease SPD 502 Stroke

Product Indication

Pre-clinical Phase I Phase II Phase III Registration Marketed FoznolTM Hyperphosphataemia

Metabolic disease

Balsalazide Ulcerative colitis EmitasolTM Diabetic gastroparesis PentasaTM 500mg Ulcerative colitis

Gastroenterology Oncology / Haematology

SPD 424 Prostate cancer SPD 427 Oncology AgrylinTM Thrombocythaemia

Development Pipeline Development Pipeline

SLIDE 8

8

A

Reminyl™ (galantamine) Reminyl™ (galantamine)

UK NICE* announce treatments for Alzheimer’s disease

should be made available as part of the management of the disease in the UK

FDA approval letter received 28 February 2001
Launch planned for May 2001 by Janssen Pharmaceutica

and Ortho McNeil in the US.

UK NICE* announce treatments for Alzheimer’s disease

should be made available as part of the management of the disease in the UK

FDA approval letter received 28 February 2001
Launch planned for May 2001 by Janssen Pharmaceutica

and Ortho McNeil in the US.

* National Institute for Clinical Excellence

SLIDE 9

9

A

Foznol* Foznol*

First European filing submitted on 13 March 2001
US filing expected by late Q4 2001
First European filing submitted on 13 March 2001
US filing expected by late Q4 2001

*Trade Mark under registration

SLIDE 10

10

A

Adderall XR* (SLI 381) Adderall XR* (SLI 381)

Intended Trade Mark Adderall XR*
Phase III data to be presented at the annual meeting of

the American Psychiatric Association (APA) on 9 May 2001 at 11:00 am

Intended Trade Mark Adderall XR*
Phase III data to be presented at the annual meeting of

the American Psychiatric Association (APA) on 9 May 2001 at 11:00 am

*Trade Mark under registration

SLIDE 11

11

A

Agrylin* Agrylin*

European Commission granted orphan drug

designation for anagrelide in treatment of essential thrombocythaemia

Orphan drug status already granted in US and

Japan

European Commission granted orphan drug

designation for anagrelide in treatment of essential thrombocythaemia

Orphan drug status already granted in US and

Japan

*Trade Mark

SLIDE 12

12

A

Angus Russell Angus Russell Group Finance Director Shire Pharmaceuticals Group plc Group Finance Director Shire Pharmaceuticals Group plc

SLIDE 13

13

A Key Product Sales Q1 01 vs Q1 00 Key Product Sales Q1 01 vs Q1 00 +31 +112 3.6 7.6 ProAmatine +43 +72 5.6 9.6 Carbatrol +10 +39 10.3 14.4 Pentasa +42 +56 11.0 17.1 Agrylin +20 +29 54.5 70.1 Adderall Scrip* Growth % Sales Growth % Q1 00 $m Q1 01 $m

*IMS Data

SLIDE 14

14

A Financial Ratios (before exceptional charges and APB 25 charge) Financial Ratios (before exceptional charges and APB 25 charge)

18 28 25 27 Operating margin 34 30 31 33 S,G&A (excl D&A) : Product sales 40 35 36 37 S,G&A (incl D&A) : Revenues 19 21 22 17 R&D : Revenues 76 82 82 82 Gross margin 24 18 18 18 COGS : Product sales FY99 % FY00 % Q1-00 % Q1-01 %

SLIDE 15

15

A

$18m Product acquisitions
$2m Fixed Assets

Financing +$2m Cash generation +$71m

Cash Flow Q1 2001 Cash Flow Q1 2001

$14m

Tax/interest Net cash surplus +$39m

SLIDE 16

16

A Balance Sheet Balance Sheet Nil 97 762 31.3.01 $m 1% (8) 631 31.3.00 $m Nil 58 753 31.12.00 $m Gearing Net Cash Net Assets

SLIDE 17

17

A

Rolf Stahel Rolf Stahel Chief Executive Shire Pharmaceuticals Group plc Chief Executive Shire Pharmaceuticals Group plc

SLIDE 18

18

A Q1 Summary Q1 Summary

Revenue growth 31%
EPS growth 46%
Reminyl* US approval expected May 2001. Launch by

Janssen Pharmaceutica and Ortho McNeil

First European filing of Foznol*
Agrylin* receives orphan drug status in Europe
Extension applied for. Shire remains firmly committed to

gaining Industry Canada’s approval to complete the proposed merger with BioChem Pharma Inc

Revenue growth 31%
EPS growth 46%
Reminyl* US approval expected May 2001. Launch by

Janssen Pharmaceutica and Ortho McNeil

First European filing of Foznol*
Agrylin* receives orphan drug status in Europe
Extension applied for. Shire remains firmly committed to

gaining Industry Canada’s approval to complete the proposed merger with BioChem Pharma Inc *Trade mark

SLIDE 19